Main outcome measures
Change in scores on the Clinical Global Impression Scale (CGIS), the Brief Psychiatric Rating Scale (BPRS), and the Scale for the Assessment of Positive Symptoms (SAPS) for psychosis and the Unified Parkinson's Disease Rating Scale (UPDRS) for parkinsonism.
Main results
The mean daily dose of clozapine at study end was 24.7 mg. Patients who received clozapine improved more than patients who received placebo in all measures of psychosis: decrease in CGIS score (p < 0.001), BPRS score (p = 0.002), modified BPRS score (p = 0.003), and SAPS score (p = 0.01) (table). Parkinsonism was not worsened in either group and the groups did not differ for total UPDRS score (p = 0.36); clozapine had a beneficial effect on tremor (p = 0.02) (table). Leukopenia developed in 1 patient during the double blind trial and in another patient during a 3 month follow up safety study necessitating discontinuation of clozapine.
Conclusion
In patients with Parkinson's disease and psychosis, clozapine, < 50 mg/day improved psychosis without worsening parkinsonism. 
Sources of funding: in part, Orphan Drug Division of the Food and Drug Administration and the

Commentary
Clozapine's selectivity for limbic, as opposed to striatal, dopamine receptors may explain why it is less likely than typical neuroleptics to produce extrapyramidal side effects. The Parkinson Study Group have confirmed that, even in patients with Parkinson's disease, clozapine can be used to treat psychosis without making parkinsonism worse. Positive symptoms, as assessed using SAPS, seemed particularly sensitive with clozapine producing a halving of SAPS score from a mean baseline score of 21 (range of possible scores 0-176, higher score indicating more severe psychosis).
The patients had fairly stable psychosis and were presumably on moderately large doses of levodopa. Almost one third were taking pergolide. Thus we can assume that the majority had drug induced psychosis, although this is not entirely clear from the entry criteria. Only 4 patients were on anticholinergics.
The study easily achieved its target of being powerful enough to rule out a clinically significant deterioration in parkinsonism in patients on clozapine. In fact the parkinsonism scores for patients on clozapine improved (mean decrease in parkinsonism score over 4 weeks was 6.4 [SE 2.9]; baseline score was 52.0 measured using the UPDRS, possible range 0-160), and improved more than those on placebo.
Side effects were generally not troublesome, although clozapine was associated with a substantial increase in heart rate (4 beats/min), so care should be taken in those patients with unstable angina.
In the study the clozapine dose was started low (6.25 mg/d) and was increased slowly (maximum 50 mg/d). If the same treatment principles are used, olanzapine (eg, starting dose of 1 mg/d) may be an alternative treatment for psychosis in Parkinson's disease, but the patchy evidence to date suggests that olanzapine may be more likely to worsen parkinsonism. 
Clozapine v placebo for decrease in measures of psychosis and parkinsonism at 4 weeks Psychosis scales Difference in mean decrease (95% CI)*
Clinical Global Impression Scale 1.1 (0.4 to 1.8) Brief Psychiatric Rating Scale 6.7 (2.7 to 10.7) Modified Brief Psychiatric Rating Scale 6.1 (2.6 to 9.7) Scale for the Assessment of Positive Symptoms 8.0 (2.5 to 13.5) Parkinsonism scales Unified Parkinson's Disease Rating Scale, total score 2.6 ( − 4.0 to 9.2) † Unified Parkinson's Disease Rating Scale, tremor score 1.3 (0.1 to 2.6) *CI calculated from data in article. A positive score indicates that the clozapine group improved more than placebo. †Not significant.
